167 related articles for article (PubMed ID: 22568394)
21. [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension].
Martyniuk TV; Chazova IE; Masenko VP; Volkov VN; Belenkov IuN
Ter Arkh; 1998; 70(4):33-6. PubMed ID: 9612899
[TBL] [Abstract][Full Text] [Related]
22. [Effect of different angiotensin converting enzyme inhibitors on coronary collateral circulation].
Zhang XH; Ma XJ; Luo J; Shao JH; Geng QX; Zhu XL; Tang YS; Xu FY
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):592-5. PubMed ID: 15144597
[TBL] [Abstract][Full Text] [Related]
23. Chronic angiotensin-converting-enzyme inhibition improves cardiac output and fluid balance during heart failure.
Brands MW; Alonso-Galicia M; Mizelle HL; Montani JP; Hildebrandt DA; Hall JE
Am J Physiol; 1993 Feb; 264(2 Pt 2):R414-22. PubMed ID: 8447498
[TBL] [Abstract][Full Text] [Related]
24. [Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].
Giestas A; Palma I; Ramos MH
Acta Med Port; 2010; 23(4):677-88. PubMed ID: 20687997
[TBL] [Abstract][Full Text] [Related]
25. [Activation of the renin-angiotensin-aldosterone system in heart failure].
Volpe M; Tocci G; Pagannone E
Ital Heart J; 2005 May; 6 Suppl 1():16S-23S. PubMed ID: 15945296
[TBL] [Abstract][Full Text] [Related]
26. [Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].
Radzevich AE; Ditiatkov AE; Tikhonov VA
Probl Tuberk; 2001; (5):16-9. PubMed ID: 11588951
[TBL] [Abstract][Full Text] [Related]
27. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
Levens NR
Arch Int Pharmacodyn Ther; 1988; 296():131-43. PubMed ID: 2853611
[TBL] [Abstract][Full Text] [Related]
28. The renin-angiotensin-aldosterone system and fibrinolysis.
Felmeden DC; Lip GY
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the tissue reninangiotensin-aldosterone system in dogs with chronic mild regurgitation through the mitral valve.
Fujii Y; Orito K; Muto M; Wakao Y
Am J Vet Res; 2007 Oct; 68(10):1045-50. PubMed ID: 17916008
[TBL] [Abstract][Full Text] [Related]
30. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs.
Mochel JP; Fink M; Bon C; Peyrou M; Bieth B; Desevaux C; Deurinck M; Giraudel JM; Danhof M
Chronobiol Int; 2014 Jun; 31(5):715-30. PubMed ID: 24654920
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
32. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Steele JL; Henik RA; Stepien RL
Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
[TBL] [Abstract][Full Text] [Related]
33. Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.
King JN; Christinaz C; Strehlau G; Hornfeld J
J Vet Pharmacol Ther; 2018 Jun; 41(3):485-489. PubMed ID: 29392741
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations.
Kuroda K; Fukuda Y; Nakao K; Inukai T
Arzneimittelforschung; 1990 Sep; 40(9):968-73. PubMed ID: 2080946
[TBL] [Abstract][Full Text] [Related]
35. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs.
Panteri A; Kukk A; Desevaux C; Seewald W; King JN
J Vet Pharmacol Ther; 2017 Jan; 40(1):44-56. PubMed ID: 27302598
[TBL] [Abstract][Full Text] [Related]
36. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
37. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
38. An update on RAAS blockade and peritoneal membrane preservation: the ace of art.
Wontanatawatot W; Eiam-Ong S; Leelahavanichkul A; Kanjanabuch T
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S175-83. PubMed ID: 22043587
[TBL] [Abstract][Full Text] [Related]
39. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
40. The renin-angiotensin-aldosterone system: approaches to cardiac and renal therapy.
Otte M; Spier A
Compend Contin Educ Vet; 2009 Jan; 31(1):E1-7; quiz E7. PubMed ID: 19241351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
